公开(公告)号：US20080312157A1

公开(公告)日：2008-12-18

申请号：US11840921

申请日：2007-08-17

申请人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

发明人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

IPC分类号： A61K38/00 ,  C07K7/00 ,  A61P1/00

CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K7/06 ,  C07K14/605

摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。

公开(公告)号：US20110136737A1

公开(公告)日：2011-06-09

申请号：US12377856

申请日：2007-08-17

申请人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

发明人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

IPC分类号： A61K38/22 ,  C07K14/645 ,  C07K14/605 ,  A61K38/26 ,  A61P3/10 ,  A61P9/00

CPC分类号： C07K14/47 ,  A61K38/00 ,  C07K14/575 ,  C07K14/57563 ,  C07K14/605 ,  C07K2319/00

摘要： The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。

公开(公告)号：US08497240B2

公开(公告)日：2013-07-30

申请号：US12377856

申请日：2007-08-17

申请人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

发明人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

IPC分类号： A61K38/00 ,  A61K38/16 ,  A61K38/26

CPC分类号： C07K14/47 ,  A61K38/00 ,  C07K14/575 ,  C07K14/57563 ,  C07K14/605 ,  C07K2319/00

摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。

公开(公告)号：US08263545B2

公开(公告)日：2012-09-11

申请号：US11840921

申请日：2007-08-17

申请人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

发明人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

IPC分类号： A61K38/00 ,  A61P3/10

CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K7/06 ,  C07K14/605

摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。

公开(公告)号：US20090036364A1

公开(公告)日：2009-02-05

申请号：US11816095

申请日：2006-02-10

申请人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young

发明人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young

IPC分类号： A61K38/22 ,  C07K14/47 ,  A61P3/10

CPC分类号： C07K14/575 ,  C07K14/605 ,  C07K2319/00

摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。

公开(公告)号：US08404637B2

公开(公告)日：2013-03-26

申请号：US11816095

申请日：2006-02-10

申请人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young

发明人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra S. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young

IPC分类号： A61K38/00 ,  A61P3/10

CPC分类号： C07K14/575 ,  C07K14/605 ,  C07K2319/00

摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

公开(公告)号：US08895498B2

公开(公告)日：2014-11-25

申请号：US13591677

申请日：2012-08-22

申请人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra G. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

发明人： Odile Esther Levy ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra G. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

IPC分类号： A61K38/00 ,  A61P3/10 ,  C07K7/06 ,  C07K14/575

CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K7/06 ,  C07K14/605

摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

摘要翻译： 本发明一般涉及具有可选性质的新型GIP类似物和GIP杂合多肽，其可用作治疗和预防代谢性疾病和病症的药剂，例如可通过控制血浆葡萄糖水平，胰岛素水平和/或 胰岛素分泌，正性肌力作用，分解代谢作用降低，胃排空减慢。 这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，饮食失调，重症监护，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。

公开(公告)号：US20130137631A1

公开(公告)日：2013-05-30

申请号：US13591677

申请日：2012-08-22

申请人： Odile Esther LEVY ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra G. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

发明人： Odile Esther LEVY ,  Alain D. Baron ,  Lawrence J. D'Souza ,  Mary Erickson ,  Soumitra G. Ghosh ,  Michael R. Hanley ,  Samuel Janssen ,  Carolyn M. Jodka ,  Diana Y. Lewis ,  Christine M. Mack ,  David G. Parkes ,  Richard A. Pittner ,  Christopher J. Soares ,  Ved Srivastava ,  Andrew A. Young ,  Thao Le

IPC分类号： C07K14/575 ,  C07K7/06

CPC分类号： C07K14/575 ,  A61K38/00 ,  C07K7/06 ,  C07K14/605

摘要： The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

公开(公告)号：US20080207501A1

公开(公告)日：2008-08-28

申请号：US11664750

申请日：2005-10-11

申请人： Mary Erickson ,  Ved Srivastava ,  Sarah McQuaid ,  Andrew A. Young ,  Richard A. Pittner ,  Soumitra S. Ghosh

发明人： Mary Erickson ,  Ved Srivastava ,  Sarah McQuaid ,  Andrew A. Young ,  Richard A. Pittner ,  Soumitra S. Ghosh

IPC分类号： A61K38/16 ,  C07K14/00 ,  A61P9/00 ,  A61P3/00

CPC分类号： C07K14/575 ,  A61K38/00

摘要： The present invention relates to Amylin Family Polypeptide-6 (AFP-6) analogs, which include derivatives and fragments, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the AFP-6 analogs. The AFP-6 analogs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent conditions such as metabolic and cardiovascular disorders, e.g., obesity, diabetes, metabolic syndrome, myocardial ischemia, and increased cardiovascular risk.

摘要翻译： 本发明涉及淀粉蛋白家族多肽-6（AFP-6）类似物，其包括衍生物和片段，相关核酸，表达构建体，宿主细胞和用于重组生产AFP-6类似物的方法。 本发明的AFP-6类似物包括一个或多个氨基酸序列修饰。 此外，公开了治疗和预防诸如代谢和心血管疾病如肥胖症，糖尿病，代谢综合征，心肌缺血和增加的心血管风险的病症的方法和组合物。

公开(公告)号：US20160207974A1

公开(公告)日：2016-07-21

申请号：US14837705

申请日：2015-08-27

申请人： Mary Erickson ,  David C. Litzinger ,  Soumitra S. Ghosh ,  Zijian Guo ,  Caroline Ekblad ,  Jonathan D. Roth

发明人： Mary Erickson ,  David C. Litzinger ,  Soumitra S. Ghosh ,  Zijian Guo ,  Caroline Ekblad ,  Jonathan D. Roth

IPC分类号： C07K14/575 ,  C07K14/315

CPC分类号： C07K14/5759 ,  A61K38/00 ,  A61K38/22 ,  A61K38/2264 ,  C07K14/315 ,  C07K14/575 ,  C07K2319/31 ,  C07K2319/70

摘要： Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.

摘要翻译： 提供化合物尤其具有良好的作用持续时间，高效力和/或方便的给药方案，包括每周给药一次。 所述化合物是结合一种或多种生物活性多肽的白蛋白结合结构域的工程多肽。 还提供了包括脂肪营养不良，血脂异常，高脂血症，超重，肥胖，下丘脑闭经，阿尔茨海默病，瘦素缺乏症，脂肪肝疾病或糖尿病（包括I型和II型）的疾病和病症的药物组合物和治疗方法。 可以通过本文所述的化合物和方法治疗的其它疾病和病症包括非酒精性脂肪性肝炎（NASH）和非酒精性脂肪性肝病（NAFLD），代谢综合征X和亨廷顿氏病。